Analyst Price Target is $2.25
▲ +42.41% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Oncology Institute in the last 3 months. The average price target is $2.25, with a high forecast of $2.50 and a low forecast of $2.00. The average price target represents a 42.41% upside from the last price of $1.58.
Current Consensus is
Buy
The current consensus among 1 investment analysts is to buy stock in Oncology Institute. This Buy consensus rating has held steady for over two years.
The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates in three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient blood product transfusions, and patient support services. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services. It serves adult and senior cancer patients. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.
Read More